For Alzheimer’s Scientists, the Amyloid Debate Has No Easy Answers

Watching the Alzheimer’s research world from the outside over the past two years has felt like a car ride over an unpaved mountain road without a seatbelt. In 2021, the US Food and Drug Administration took the unusual step of overruling its advisory committee to approve the sale of Aduhelm, the first new Alzheimer’s drug in nearly two decades. The drug was designed to work by clearing accumulations of amyloid beta, a protein that has long been linked to the disease, from patient’s brains. In clinical trials, the drug did remove amyloid—but it didn’t convincingly improve cognition, so the committee recommended against it.

But the FDA determined that amyloid clearance

→ Continue reading at Wired - Science

More from author

Related posts

Advertisment

Latest posts

That security camera and smart doorbell you’re using may have some major security flaws | CNN Business

CNN  —  When 24-year-old Heather Hines from Southern California was changing into her work clothes last month, she...

Immerse Your Team in Microsoft’s Best Products for 20% Less Than Usual

Disclosure: Our goal is to feature products and services that we think you'll find interesting and useful. If you purchase them, Entrepreneur may...

This Polar Wolf External SSD Drive Is on Sale for $44

Disclosure: Our goal is to feature products and services that we think you'll find interesting and useful. If you purchase them, Entrepreneur may...